Top
Main
 
All Outcomes
 
RCT vs. Obs.
 
Feedback
Home
c19early.org COVID-19 treatment researchIndomethacinIndomethacin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Indomethacin for COVID-19: real-time meta analysis of 4 studies

@CovidAnalysis, November 2024, Version 3V3
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gordon (PSM) 67% 0.33 [0.04-3.15] hosp. 1/103 3/103 OT​1 Improvement, RR [CI] Treatment Control Gordon (PSM) 57% 0.43 [0.11-1.61] progression 3/103 7/103 OT​1 Ravichandran (PSM) 96% 0.04 [0.00-0.26] oxygen 1/72 28/72 OT​1 Ravichandran 43% 0.57 [0.48-0.67] recov. time 72 (n) 72 (n) OT​1 Ravichandran 54% 0.46 [0.37-0.58] recov. time 72 (n) 72 (n) OT​1 Ravichandran 62% 0.38 [0.28-0.50] recov. time 72 (n) 72 (n) OT​1 Salmasi (RCT) 66% 0.34 [0.01-7.89] ventilation 0/22 1/23 Salmasi (RCT) -40% 1.40 [0.52-3.81] recov. time 22 (n) 23 (n) Ravichandran (RCT) 30% 0.70 [0.56-0.88] no recov. 52/103 77/107 OT​1 Ravichandran (RCT) 98% 0.02 [0.00-0.41] progression 0/103 20/107 OT​1 Ravichandran (RCT) 57% 0.43 [0.33-0.55] recov. time 103 (n) 107 (n) OT​1 Ravichandran (RCT) 43% 0.57 [0.48-0.67] recov. time 103 (n) 107 (n) OT​1 Ravichandran (RCT) 43% 0.57 [0.48-0.67] recov. time 103 (n) 107 (n) OT​1 Ravichandran (RCT) 17% 0.83 [0.64-1.08] viral+ 37/62 43/60 OT​1 Indomethacin COVID-19 outcomes c19early.org November 2024 1 OT: comparison with other treatment Favors indomethacin Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit